"","drug","drug_drugbank_standard","drug_pubchem","biomarker","biomarker_ensembl_standard","biomarker_type","biomarker_direction","biomarker_relations","biomarker_description","disease","diseases_id_standard","drug_targets","QC","curator","raw_table","source","source_id","record_id"
"1","ABACAVIR","DB01048","29969962","HLA-B","ENSG00000234745","polymorphism",NA,NA,"HLA-B POLYMORPHISM NA","ADIS","Orphanet_391372","NRTI","pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG594659457"
"2","ABEMACICLIB","DB12001","46220502","ESR, ERBB2","ENSG00000091831, ENSG00000141736","protein expression, protein expression & amplification","positive, negative","AND","ESR PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION & AMPLIFICATION NEGATIVE","(HER2)-negative advanced or metastatic breast cancer","MONDO_0007254","CDK4; CDK6","pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG1498962895"
"4","AFATINIB","DB08916","10184653","EGFR","ENSG00000146648","mutation",NA,NA,"EGFR MUTATION NA","lung cancer","MONDO_0008903","EGFR (L858R); EGFR (L858R/T790M); EGFR (wt); HER2; ErbB4","pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG-1064188334"
"5","ALECTINIB","DB11363","49806720","ALK","ENSG00000171094","protein expression",NA,NA,"ALK PROTEIN EXPRESSION NA","Non-small cell lung cancer that has spread to other parts of the body","EFO_0003060","ALK; ALK (F1174L); ALK (R1275Q); INSR; VEGFR2 (KDR)","pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG-1932775397"
"6","ALPELISIB","DB12015","56649450","ESR, ERBB2, PIK3CA","ENSG00000091831, ENSG00000141736, ENSG00000121879","protein expression, protein expression & amplification,  mutation","positive, negative,positive","AND,AND","ESR PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION & AMPLIFICATION NEGATIVE AND PIK3CA MUTATION POSITIVE","Advanced or metastatic breast cancer","MONDO_0007254","PI3Kα; p110α; p110γ","pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG-955586545"
"7","AMIFAMPRIDINE","DB11640","9920716","NAT2","ENSG00000156006","polymorphism",NA,NA,"NAT2 POLYMORPHISM NA","Lambert-eaton myasthenia syndrome in adults","MONDO_0023370","potassium channel","pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG-1386474016"
"8","AMIFAMPRIDINE PHOSPHATE",NA,"9920716","NAT2","ENSG00000156006","polymorphism",NA,NA,"NAT2 POLYMORPHISM NA","Lambert-eaton syndrome","MONDO_0023370","potassium channel","pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG-1029442076"
"9","AMITRIPTYLINE","DB00321","11065","CYP2D6","ENSG00000100197","polymorphism",NA,NA,"CYP2D6 POLYMORPHISM NA","depression","EFO_0003761","5-HT; 5-HT2; 5-HT4; Norepinephrine receptor; σ1","pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG1233009142"
"10","AMOXAPINE","DB00543","2170","CYP2D6","ENSG00000100197","polymorphism",NA,NA,"CYP2D6 POLYMORPHISM NA","depression","EFO_0003761","GlyT1b; GlyT2a","pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG979588562"
"11","AMPHETAMINE","DB00182","5826","CYP2D7","ENSG00000205702","polymorphism",NA,NA,"CYP2D7 POLYMORPHISM NA","Attention deficit hyperactivity disorder,obesity","EFO_0001073",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG2008815520"
"13","ARFORMOTEROL","DB01274","3083544","UGT1A1, CYP2D6","ENSG00000241635, ENSG00000100197","polymorphism, polymorphism","positive, positive","AND/OR","UGT1A1 POLYMORPHISM POSITIVE AND/OR CYP2D6 POLYMORPHISM POSITIVE","Chronic obstructive pulmonary disease","EFO_0000341","β2-adrenergic receptor","pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG445115987"
"14","ARIPIPRAZOLE   LAUROXIL",NA,"49831411","CYP2D6","ENSG00000100197","polymorphism",NA,NA,"CYP2D6 POLYMORPHISM NA","Schizophrenia and bipolar disorder,Major depression,Tourette's disease or autism","EFO_0000289","5-HT2A","pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG-493957746"
"15","ARSENIC TRIOXIDE","DB01169",NA,"PML-RARA","ENSG00000133246","translocation",NA,NA,"PML-RARA TRANSLOCATION NA","blood and bone marrow cancers","MONDO_0021138","HK2(Hexokinase 2)","pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG1476585244"
"16","ARTICAINE, EPINEPHRINE","DB09009,DB00668","32170, 5816","G6PD","ENSG00000160211","protein expression",NA,NA,"G6PD PROTEIN EXPRESSION NA","Anesthesiology,before dental care to numb the area","OTAR_0000018",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG-1745727063"
"17","ATEZOLIZUMAB","DB11595",NA,"CD274","ENSG00000120217","protein expression",NA,NA,"CD274 PROTEIN EXPRESSION NA","Breast bladder and urinary tract cancers, non-small cell lung cancer.","MONDO_0007254","hPD-L1","pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG1850603683"
"19","ATEZOLIZUMAB","DB11595",NA,"CD274，EGFR，ALK","ENSG00000120217, ENSG00000146648, ENSG00000171094","protein expression, mutation, mutation","positive, negative, negative","AND, AND","CD274 PROTEIN EXPRESSION POSITIVE AND EGFR MUTATION NEGATIVE AND ALK MUTATION NEGATIVE"," non-small cell lung cancer.","EFO_0003060",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG1616970176"
"20","ATOMOXETINE","DB00289","54841","CYP2D6","ENSG00000100197","polymorphism",NA,NA,"CYP2D6 POLYMORPHISM NA","Hyperactive attention deficit","EFO_0003888","5-HT; DA transporter; Norepinephrine (NE) transporter","pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG-292801829"
"24","AZATHIOPRINE","DB00993","2265","TPMT, NUDT15","ENSG00000137364, ENSG00000136159","polymorphism, polymorphism","negative, negative","AND/OR","TPMT POLYMORPHISM NEGATIVE AND/OR NUDT15 POLYMORPHISM NEGATIVE","Autoimmune diseases","EFO_1000870","HGPRT; Rac1;","pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG1048595055"
"25","BELINOSTAT","DB05015","6918638","UGT1A1","ENSG00000241635","polymorphism",NA,NA,"UGT1A1 POLYMORPHISM NA","T cell lymphoma","EFO_0002913","HDAC","pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG2059480590"
"26","BINIMETINIB","DB11967","10288191","BRAF","ENSG00000157764","mutation",NA,NA,"BRAF MUTATION NA","melanoma","EFO_0000756","MEK1&2","pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG736314554"
"28","BOCEPREVIR","DB08873","10324367","IFNL3
","ENSG00000197110","protein expression",NA,NA,"IFNL3 PROTEIN EXPRESSION NA","Hepatitis c infection","EFO_0004220","HCV NS3 protease","pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG-378943012"
"32","BREXPIPRAZOLE","DB09128","11978813","CYP2D6","ENSG00000100197","polymorphism",NA,NA,"CYP2D6 POLYMORPHISM NA","schizophrenia,Severe depression,Alzheimer's disease","EFO_0000249",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG829815143"
"33","BRIGATINIB","DB12267","68165256","ALK","ENSG00000171094","mutation",NA,NA,"ALK MUTATION NA","Non-small cell lung cancer that has spread to other parts of the body","EFO_0003060",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG1437695799"
"34","BRIVARACETAM","DB05541","9837243","CYP2C19","ENSG00000165841","polymorphism",NA,NA,"CYP2C19 POLYMORPHISM NA","epilepsy","EFO_0000474",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG282615554"
"35","CABOZANTINIB","DB08875","25102846","RET","ENSG00000165731","genetic others",NA,NA,"RET GENETIC OTHERS NA","non-small-cell lung cancer","EFO_0003060",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG816316872"
"36","CAPECITABINE","DB01101","60953","DPYD","ENSG00000188641","mutation",NA,NA,"DPYD MUTATION NA","Colorectal cancer,reast cancer","EFO_0005842",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG1533469514"
"37","CARBAMAZEPINE","DB00564","2554","HLA-B, HLA-A","ENSG00000234745, ENSG00000206503","polymorphism, polymorphism","negative, negative","AND/OR","HLA-B POLYMORPHISM NEGATIVE AND/OR HLA-A POLYMORPHISM NEGATIVE","Brivaracetam,epilepsy,anticonvulsants","EFO_0000474",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG205847830"
"38","CARGLUMIC ACID","DB06775","121396","NAGS","ENSG00000161653","protein expression",NA,NA,"NAGS PROTEIN EXPRESSION NA","Inborn Errors of Metabolism,high ammonia levels","Orphanet_68367",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG541509081"
"39","CARIPRAZINE","DB06016","25096873","CYP2D6","ENSG00000100197","polymorphism",NA,NA,"CYP2D6 POLYMORPHISM NA","schizophrenia,Bipolar I disorder","EFO_0000289",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG1069940068"
"40","CARISOPRODOL","DB00395","2576","CYP2C19","ENSG00000165841","polymorphism",NA,NA,"CYP2C19 POLYMORPHISM NA","Skeletal muscle diseas","Orphanet_206634",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG1900108140"
"41","CARVEDILOL","DB01136","185395","CYP2D6","ENSG00000100197","polymorphism",NA,NA,"CYP2D6 POLYMORPHISM NA","Heart failure,high blood pressure,Heart disease","EFO_0003777",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG-1557071629"
"42","CELECOXIB","DB00482","2662","CYP2C9","ENSG00000138109","polymorphism",NA,NA,"CYP2C9 POLYMORPHISM NA","Arthritis, ankylosis and menstrual pain,Rheumatoid arthritis","EFO_0000685",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG900270885"
"43","CEFTRIAXONE","DB01212","5479530","G6PD","ENSG00000160211","polymorphism",NA,NA,"G6PD POLYMORPHISM NA","Treat or prevent bacterial infections","EFO_0000771",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG570155103"
"44","CERITINIB","DB09063","57379345","ALK","ENSG00000171094","mutation",NA,NA,"ALK MUTATION NA","Lung cancer","MONDO_0008903",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG-413895656"
"45","CERLIPONASE ALFA","DB13173",NA,"TPP1","ENSG00000166340","mutation",NA,NA,"TPP1 MUTATION NA","Type 2 disease of ceroid lipofuscinosis (CLN2)","EFO_1000051",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG-2121880163"
"46","CETUXIMAB","DB00002","136170999","RAS","ENSG00000133703","mutation",NA,NA,"RAS MUTATION NA","cancer of the head and neck","EFO_0006859",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG1928793512"
"47","CRIZANLIZUMAB","DB15271",NA,"HBB","ENSG00000244734","mutation",NA,NA,"HBB MUTATION NA","people with sickle cell disease","EFO_1000636",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG1667727299"
"48","CRIZOTINIB","DB08865","11626560","ROS1","ENSG00000047936","gene fusion",NA,NA,"ROS1 GENE FUSION NA"," lung cancer","MONDO_0008903",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG-1839732767"
"49","DABRAFENIB","DB08912","44462760","RAS","ENSG00000133703","mutation",NA,NA,"RAS MUTATION NA","skin cancer (melanoma)","MONDO_0002898",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG-1229781644"
"50","DENILEUKIN DIFTITOX","DB00004",NA,"IL2RA
","ENSG00000134460","protein expression",NA,NA,"IL2RA PROTEIN EXPRESSION NA","leukemia","EFO_0000565",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG-210842937"
"52","EFAVIRENZ","DB00625","64139","CYP2B6","ENSG00000197408","polymorphism",NA,NA,"CYP2B6 POLYMORPHISM NA"," HIV infection","EFO_0000764",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG779147928"
"53","ELAGOLIX","DB11979","11250647","SLCO1B1","ENSG00000134538","protein expression",NA,NA,"SLCO1B1 PROTEIN EXPRESSION NA","moderate to severe pain caused by endometriosis.","EFO_0003843",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG-1440571084"
"59","ENASIDENIB","DB13874","89683805","IDH2","ENSG00000182054","mutation",NA,NA,"IDH2 MUTATION NA","acute myeloid leukemia (AML) in adults with an IDH2 mutation.","EFO_0000222",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG-1362059301"
"61","ENTRECTINIB","DB11986","25141092","NTRK","ENSG00000165300","gene fusion",NA,NA,"NTRK GENE FUSION NA","Solid tumor","Orphanet_84",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG-622383070"
"63","ESCITALOPRAM","DB01175","146570","CYP2C19","ENSG00000165841","polymorphism",NA,NA,"CYP2C19 POLYMORPHISM NA","Depression","EFO_0003761",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG-1869766997"
"65","ETEPLIRSEN","DB06014",NA,"DMD","ENSG00000198947","mutation",NA,NA,"DMD MUTATION NA","Duchenne muscular dystrophy","Orphanet_98896",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG-998821726"
"66","FLUOROURACIL","DB00544","3385","DPYD","ENSG00000188641","mutation",NA,NA,"DPYD MUTATION NA","skin cancer","MONDO_0002898",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG363506879"
"67","GILTERITINIB","DB12141","49803313","FLT3","ENSG00000122025","mutation",NA,NA,"FLT3 MUTATION NA","myelomatosis","EFO_0001378",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG-23249570"
"70","IMATINIB","DB00619","123596","KIT，FIP1L1-PDGFRA","ENSG00000157404, ENSG00000282278","mutation, gene fusion","negative, positive","AND","KIT MUTATION NEGATIVE AND FIP1L1-PDGFRA GENE FUSION POSITIVE","Aggressive Systemic Mastocytosis","EFO_0000618",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG1859447834"
"72","IMATINIB","DB00619","123596","PDGFRB","ENSG00000113721","translocation",NA,NA,"PDGFRB TRANSLOCATION NA","Myelodysplastic","MONDO_0020077",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG1151651722"
"73","IMATINIB","DB00619","123596","FIP1L1-PDGFRA","ENSG00000282278","gene fusion",NA,NA,"FIP1L1-PDGFRA GENE FUSION NA","Hypereosinophilic Syndrome (HES) and","EFO_0004842",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG-1147713356"
"74","INDACATEROL","DB05039","6918554","UGT1A1","ENSG00000241635","polymorphism",NA,NA,"UGT1A1 POLYMORPHISM NA","asthma","EFO_0000270",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG166414512"
"75","INOTERSEN","DB14713","121493436","TTR","ENSG00000118271","protein expression",NA,NA,"TTR PROTEIN EXPRESSION NA","FAP(Familial amyloid polyneuropathy)","EFO_0002945",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG-539500812"
"76","IPILIMUMAB","DB06186",NA,"HLA-A","ENSG00000206503","polymorphism",NA,NA,"HLA-A POLYMORPHISM NA","Melanoma","EFO_0000756",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG-848100356"
"77","ISOSORBIDE DINITRATE","DB00883","6883","CYB5R","ENSG00000100243","protein expression",NA,NA,"CYB5R PROTEIN EXPRESSION NA","angina","EFO_0003913",NA,"pass","Ben","FDA-drug&biomarkers-v8.xlsx","FDA","NA","BiomarkerKG1476229835"
"80","SACITUZUMAB GOVITECAN, TALAZOPARIB","DB12893,DB11760","91668186, 135565082","ESR1, PR, ERBB2","ENSG00000091831, ENSG00000134551, ENSG00000141736","protein expression, protein expression, protein expression & amplification","negative, negative,negative","AND,AND","ESR1 PROTEIN EXPRESSION NEGATIVE AND PR PROTEIN EXPRESSION NEGATIVE AND ERBB2 PROTEIN EXPRESSION & AMPLIFICATION NEGATIVE","stage IV (metastatic) breast cancer","MONDO_0007254",NA,"pass","Ben","Breast_cancer_CLINICALTRIAL_v7.xlsx","clinicaltrials.gov","NCT04039230","BiomarkerKG650370835"
"81","TRASTUZUMAB, GDC-0084","DB00072,DB15186","3001322, 57384863","ERBB2","ENSG00000141736","protein expression & amplification","positive",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","Breast cancer with progressive brain metastases","MONDO_0007254","HER2, PI3-kinase","pass","Ben","Breast_cancer_CLINICALTRIAL_v7.xlsx","clinicaltrials.gov","NCT03765983","BiomarkerKG-1577117464"
"82","NERATINIB, FULVESTRANT","DB11828,DB00947","9915743, 104741","ERBB2,ESR1","ENSG00000141736, ENSG00000091831","protein expression & amplification, protein expression","positive,positive","AND","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","Metastatic Breast Cancer","EFO_1000984","HER2","pass","Ben","Breast_cancer_CLINICALTRIAL_v7.xlsx","clinicaltrials.gov","NCT03289039","BiomarkerKG1651699518"
"83","NIVOLUMAB, CABOZANTINIB","DB09035,DB08875","NA, 25102846","ESR1, PR, ERBB2","ENSG00000091831, ENSG00000134551, ENSG00000141736","protein expression, protein expression, protein expression & amplification","negative, negative,negative","AND,AND","ESR1 PROTEIN EXPRESSION NEGATIVE AND PR PROTEIN EXPRESSION NEGATIVE AND ERBB2 PROTEIN EXPRESSION & AMPLIFICATION NEGATIVE","Metastatic Triple-negative Breast Cancer","MONDO_0007254",NA,"pass","Ben","Breast_cancer_CLINICALTRIAL_v7.xlsx","clinicaltrials.gov","NCT03316586","BiomarkerKG-56300326"
"84","VINORELBINE, TRASTUZUMAB, AVELUMAB, UTOMILUMAB","DB00361,DB00072,DB11945,DB15113","5311497, 3001322, NA, NA","ERBB2, PD1","ENSG00000141736, ENSG00000145335","protein, protein","positive,positive","AND","ERBB2 PROTEIN POSITIVE AND PD1 PROTEIN POSITIVE","Advanced HER2+ Breast Cancer","MONDO_0007254","PD1 ,HER2","pass","Ben","Breast_cancer_CLINICALTRIAL_v7.xlsx","clinicaltrials.gov","NCT03414658","BiomarkerKG1866168183"
"85","FULVESTRANT, ENZALUTAMIDE","DB00947,DB08899","104741, 15951529","ESR1,ERBB2","ENSG00000091831, ENSG00000141736","protein expression & amplification, protein expression","positive,negative","AND","ESR1 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","Her2- Advanced Breast Cancer","MONDO_0007254",NA,"pass","Ben","Breast_cancer_CLINICALTRIAL_v7.xlsx","clinicaltrials.gov","NCT02953860","BiomarkerKG1845581618"
"87","CARBOPLATIN, PACLITAXEL","DB00958,DB01229","56840877, 36314","HER2","ENSG00000141736","protein","negative",NA,"HER2 PROTEIN NEGATIVE","HER2 (human epidermal growth factor 2) -negative breast adenocarcinoma","EFO_0000305",NA,"pass","Ben","Breast_cancer_CLINICALTRIAL_v7.xlsx","clinicaltrials.gov","NCT02546232","BiomarkerKG-1857510214"
"90","PYROTINIB, FULVESTRANT","DB14993,DB00947","51039030, 104741","ESR1,PR,ERBB2","ENSG00000091831, ENSG00000134551, ENSG00000141736","protein expression, protein expression, protein expression & amplification","positive,positive,positive","AND,AND","ESR1 PROTEIN EXPRESSION POSITIVE AND PR PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","HER2+ Metastatic Breast Cancer","MONDO_0007254",NA,"pass","Ben","Breast_cancer_CLINICALTRIAL_v7.xlsx","clinicaltrials.gov","NCT04033172","BiomarkerKG-384148472"
"91","T-DM1","DB05773",NA,"ERBB2","ENSG00000141736","protein & DNA","positive",NA,"ERBB2 PROTEIN & DNA POSITIVE","Stage I-III breast cancer","MONDO_0007254",NA,"pass","Ben","Breast_cancer_CLINICALTRIAL_v7.xlsx","clinicaltrials.gov","NCT03587740","BiomarkerKG-898666061"
"95","GEDATOLISIB, PTK7-ADC","DB11896,NA","44516953, NA","ESR1,PR,ERBB2","ENSG00000091831, ENSG00000134551, ENSG00000141736","protein expression, protein expression, protein expression & amplification","negative, negative,negative","AND,AND","ESR1 PROTEIN EXPRESSION NEGATIVE AND PR PROTEIN EXPRESSION NEGATIVE AND ERBB2 PROTEIN EXPRESSION & AMPLIFICATION NEGATIVE","Metastatic Triple-negative Breast Cancer","MONDO_0007254",NA,"pass","Ben","Breast_cancer_CLINICALTRIAL_v7.xlsx","clinicaltrials.gov","NCT03243331","BiomarkerKG350394115"
"96","RUXOLITINIB, CAPECITABINE","DB08877,DB01101","25126798, 60953","ERBB2","ENSG00000141736","protein","negative",NA,"ERBB2 PROTEIN NEGATIVE","Advanced or Metastatic HER2-negative Breast Cancer","MONDO_0007254",NA,"pass","Ben","Breast_cancer_CLINICALTRIAL_v7.xlsx","clinicaltrials.gov","NCT02120417","BiomarkerKG-231956791"
"97","VINORELBINE, LETROZOLE, ANASTROZOLE","DB00361,DB01006,DB01217","5311497, 3902, 2187","ESR1,PR,ERBB2","ENSG00000091831, ENSG00000134551, ENSG00000141736","protein expression, protein expression, protein expression & amplification","positive,positive,negative","AND,AND","ESR1 PROTEIN EXPRESSION POSITIVE AND PR PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION & AMPLIFICATION NEGATIVE","Pretreated Metastatic Breast Cancer","MONDO_0007254",NA,"pass","Ben","Breast_cancer_CLINICALTRIAL_v7.xlsx","clinicaltrials.gov","NCT02585388","BiomarkerKG1161470093"
"98","TRASTUZUMAB, LEUKINE","DB00072,NA","3001322, NA","HER2,HLA2, HLAA3, HLAA24, HLAA26,","ENSG00000141736, NA, NA, NA, NA","polymorphism, polymorphism, polymorphism, polymorphism, protein expression & amplification","positive,positive,positive,positive,positive","AND, OR,OR,OR","HER2 POLYMORPHISM POSITIVE AND HLA2 POLYMORPHISM POSITIVE OR HLAA3 POLYMORPHISM POSITIVE OR HLAA24 POLYMORPHISM POSITIVE OR HLAA26 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","High-risk HER2+ Breast Cancer","MONDO_0007254",NA,"pass","Ben","Breast_cancer_CLINICALTRIAL_v7.xlsx","clinicaltrials.gov","NCT02297698","BiomarkerKG-2021518099"
"100","OLAPARIB, CARBOPLATIN, ANTHRACYCLINE, CYCLOPHOSPHAMIDE","DB09074,DB00958,NA,DB00531","23725625, 56840877, NA, 2907","ERBB2","ENSG00000141736","protein expression,","negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","Advanced HER2 Negative Breast Cancer","MONDO_0007254",NA,"pass","Ben","Breast_cancer_CLINICALTRIAL_v7.xlsx","clinicaltrials.gov","NCT02561832","BiomarkerKG1930391039"
"101","DISULFIRAM, VINORELBIN, CISPLATIN, COPPER","DB00822,DB00361,DB00515,DB09130","3117, 44424639, 135804801, 23978","ESR1, PR, ERBB2","ENSG00000091831, ENSG00000134551, ENSG00000141736","protein expression, protein expression,protein expression,","positive,positive,negative","AND,AND","ESR1 PROTEIN EXPRESSION POSITIVE AND PR PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","Refractory Metastatic Breast Cancer","MONDO_0007254",NA,"pass","Ben","Breast_cancer_CLINICALTRIAL_v7.xlsx","clinicaltrials.gov","NCT04265274","BiomarkerKG-129847157"
"102","RIBOCICLIB, T-DM1, TRASTUZUMAB, FULVESTRANT","DB11730,DB05773,DB00072,DB00947","44631912, NA, 3001322, 104741","ESR1, HER2","ENSG00000091831, ENSG00000141736","protein expression, protein expression & DNA","positive,positive","AND","ESR1 PROTEIN EXPRESSION POSITIVE AND HER2 PROTEIN EXPRESSION & DNA POSITIVE","Metastatic Her2-Positive Breast Cancer","MONDO_0007254","Cyclin-Dependent Kinases (CDKs),HER2, ,","pass","Ben","Breast_cancer_CLINICALTRIAL_v7.xlsx","clinicaltrials.gov","NCT02657343","BiomarkerKG1480637455"
"103","CARBOPLATIN, EVEROLIMUS","DB00958,DB01590","56840877, 6442177","ESR1,PR,ERBB2","ENSG00000091831, ENSG00000134551, ENSG00000141736","protein expression, protein expression, protein expression","negative, negative,negative","AND,AND","ESR1 PROTEIN EXPRESSION NEGATIVE AND PR PROTEIN EXPRESSION NEGATIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","Advanced Triple-Negative Breast Cancer","MONDO_0007254",NA,"pass","Ben","Breast_cancer_CLINICALTRIAL_v7.xlsx","clinicaltrials.gov","NCT02531932","BiomarkerKG-1181188759"
"104","PALBOCICLIB, LETROZOLE","DB09073,DB01006","11431660, 3902","ESR1, PR, ERBB2","ENSG00000091831, ENSG00000134551, ENSG00000141736","protein expression, protein expression, protein expression","positive,positive,negative","AND,AND","ESR1 PROTEIN EXPRESSION POSITIVE AND PR PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","HR+, HER2- Advanced Breast Cancer","MONDO_0007254",NA,"pass","Ben","Breast_cancer_CLINICALTRIAL_v7.xlsx","clinicaltrials.gov","NCT02679755","BiomarkerKG-523699566"
"105","CELECOXIB","DB00482","2662","HER2","ENSG00000141736","protein expression","negative",NA,"HER2 PROTEIN EXPRESSION NEGATIVE","Primary Breast Cancer","MONDO_0007254",NA,"pass","Ben","Breast_cancer_CLINICALTRIAL_v7.xlsx","clinicaltrials.gov","NCT02429427","BiomarkerKG478084554"
"107","ENTINOSTAT, EXEMESTANE","DB11841,DB00990","4261, 60198","ESR1,PR","ENSG00000091831, ENSG00000134551","protein expression, protein expression","positive,positive","AND","ESR1 PROTEIN EXPRESSION POSITIVE AND PR PROTEIN EXPRESSION POSITIVE","Recurrent or Metastatic Breast Cancer","MONDO_0007254",NA,"pass","Ben","Breast_cancer_CLINICALTRIAL_v7.xlsx","clinicaltrials.gov","NCT02833155","BiomarkerKG-601071095"
"108","TRASTUZUMAB","DB00072","3001322","ERBB2","ENSG00000141736","protein expression & amplification","positive",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","metastasis breast cancer","MONDO_0007254",NA,"pass","Ben","Breast_cancer_CLINICALTRIAL_v7.xlsx","clinicaltrials.gov","NCT01325207","BiomarkerKG-1855863757"
"109","LETROZOLE, TAMOXIFEN, PALBOCICLIB, ENDOCRINE THERAPY","DB01006,DB00675,DB09073,NA","3902, 2733526, 11431660, NA","ESR1, PR, ERBB2","ENSG00000091831, ENSG00000134551, ENSG00000141736","protein expression, protein expression, protein expression & amplification","positive, positive, negative","AND/OR,AND","ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PR PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION & AMPLIFICATION NEGATIVE","Stage I to III histologically confirmed invasive carcinoma","MONDO_0040677",NA,"pass","Ben","Breast_cancer_CLINICALTRIAL_v7.xlsx","clinicaltrials.gov","NCT02764541","BiomarkerKG2105163997"
"110","ZOLEDRONIC ACID","DB00399","68740","ESR1, PR, ERBB2","ENSG00000091831, ENSG00000134551, ENSG00000141736","protein expression, protein expression, protein expression & amplification","negative, negative,negative","AND,AND","ESR1 PROTEIN EXPRESSION NEGATIVE AND PR PROTEIN EXPRESSION NEGATIVE AND ERBB2 PROTEIN EXPRESSION & AMPLIFICATION NEGATIVE","Triple-negative breast cancer","EFO_0005537",NA,"pass","Ben","Breast_cancer_CLINICALTRIAL_v7.xlsx","clinicaltrials.gov","NCT04045522","BiomarkerKG-26493458"
"111","BEVACIZUMAB, PACLITAXEL","DB00112,DB01229","NA, 36314","ERBB2","ENSG00000141736","protein expression & amplification","negative",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION NEGATIVE","HER2-negative Metastatic Breast Cancer","MONDO_0007254",NA,"pass","Ben","Breast_cancer_CLINICALTRIAL_v7.xlsx","clinicaltrials.gov","NCT01722968","BiomarkerKG1564751338"
"112","TRASTUZUMAB, ERIBULIN, ERIBULIN MESYLATE","DB00072,DB08871,NA","3001322, 11354606, 17755248","ERBB2","ENSG00000141736","protein expression & amplification","positive",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","HER2-positive advanced or recurrent Breast Cancer","MONDO_0007254",NA,"pass","Ben","Breast_cancer_CLINICALTRIAL_v7.xlsx","clinicaltrials.gov","NCT01432886","BiomarkerKG117510885"
"113","BEVACIZUMAB","DB00112",NA,"ALDH1","ENSG00000165092","protein expression","positive",NA,"ALDH1 PROTEIN EXPRESSION POSITIVE","Primary breast cancer","MONDO_0007254",NA,"pass","Ben","Breast_cancer_CLINICALTRIAL_v7.xlsx","clinicaltrials.gov","NCT01190345","BiomarkerKG1152699269"
"114","VINORELBINE, TRASTUZUMAB EMTANSINE","DB00361,DB05773","5311497, NA","ERBB2","ENSG00000141736","protein expression & amplification","positive",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","Pre-Treated HER2-Positive Metastatic Breast Cancer","MONDO_0007254",NA,"pass","Ben","Breast_cancer_CLINICALTRIAL_v7.xlsx","clinicaltrials.gov","NCT02658084","BiomarkerKG1851134241"
"115","ABEMACICLIB, STANDARD ADJUVANT ENDOCRINE THERAPY","DB12001,NA","46220502, NA","ESR1, PR, HER2, ki-67","ENSG00000091831, ENSG00000134551, ENSG00000141736, ENSG00000148773","protein expression, protein expression, protein expression & amplification, protein expression","positive, positive, negative, ≥20%","AND,AND,AND","ESR1 PROTEIN EXPRESSION POSITIVE AND PR PROTEIN EXPRESSION POSITIVE AND HER2 PROTEIN EXPRESSION & AMPLIFICATION NEGATIVE AND KI-67 PROTEIN EXPRESSION ≥20%","High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer","EFO_0005537",NA,"pass","Ben","Breast_cancer_CLINICALTRIAL_v7.xlsx","clinicaltrials.gov","NCT03155997","BiomarkerKG1910318456"
"116","FORETINIB, LAPATINIB","DB12307,DB01259","42642645, 208908","ERBB2","ENSG00000141736","protein expression & amplification","positive",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","HER2 positive invasive breast cancer","MONDO_0007254",NA,"pass","Ben","Breast_cancer_CLINICALTRIAL_v7.xlsx","clinicaltrials.gov","NCT01138384","BiomarkerKG2134783297"
"117","RAMUCIRUMAB, ERIBULIN","DB05578,DB08871","NA, 11354606","ERBB2","ENSG00000141736","protein expression & amplification","positive",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","invasive breast cancer","EFO_1000307",NA,"pass","Ben","Breast_cancer_CLINICALTRIAL_v7.xlsx","clinicaltrials.gov","NCT01427933","BiomarkerKG257039608"
"121","APATINIB, PACLITAXEL, CISPLATIN","DB14765,DB01229,DB00515","45139106, 36314, 135804801","ESR1, PR","ENSG00000091831, ENSG00000134551","protein expression, protein expression","negative, negative","AND","ESR1 PROTEIN EXPRESSION NEGATIVE AND PR PROTEIN EXPRESSION NEGATIVE","breast invasive carcinoma","EFO_0000305",NA,"pass","Ben","Breast_cancer_CLINICALTRIAL_v7.xlsx","clinicaltrials.gov","NCT03580395","BiomarkerKG-129758161"
"126","ENTINOSTAT, CAPECITABINE","DB11841,DB01101","4261, 60953","ESR1, PR, ERBB2","ENSG00000091831, ENSG00000134551, ENSG00000141736","protein expression, protein expression, protein expression","Positve/negative, positive/negative, negative","OR, AND","ESR1 PROTEIN EXPRESSION POSITVE/NEGATIVE OR PR PROTEIN EXPRESSION POSITIVE/NEGATIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","Metastatic Breast Cancer, Breast Cancer","MONDO_0007254","HDAC, DNA/RNA/Protein Synthesis","pass","Tyler","Breast Cancer (LT NCT04194684, 1-50)_tyler.xlsx","clinicaltrials.gov","NCT03473639","BiomarkerKG-1684481490"
"127","TALAZOPARIB, SACITUZUMAB GOVITECAN","DB11760,DB12893","135565082, 91668186","ESR1, PR, ERBB2","ENSG00000091831, ENSG00000134551, ENSG00000141736","protein expression, protein expression, protein expression","Negative, negative, negative","AND, AND","ESR1 PROTEIN EXPRESSION NEGATIVE AND PR PROTEIN EXPRESSION NEGATIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","Metastatic Triple-Negative Breast Cancer","MONDO_0007254","PARP, Topoisomerase I-DNA covalent complexes","pass","Tyler","Breast Cancer (LT NCT04194684, 1-50)_tyler.xlsx","clinicaltrials.gov","NCT04039230","BiomarkerKG669266934"
"128","TRASTUZUMAB, GDC-0084","DB00072,DB15186","3001322, 57384863","ERBB2","ENSG00000141736","protein expression & amplification","Positve",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITVE","EBBR2-Positive Breast Cancer Brain Metastases","MONDO_0007254","EBBR2, PI3-Kinase","pass","Tyler","Breast Cancer (LT NCT04194684, 1-50)_tyler.xlsx","clinicaltrials.gov","NCT03765983","BiomarkerKG-1577117464"
"129","ASPIRIN, TAMOXIFEN, DOXORUBICIN, CYCLOPHOSPHAMIDE, PACLITAXEL","DB00945,DB00675,DB00997,DB00531,DB01229","2244, 2733526, 443939, 2907, 36314","ESR1, ERBB2","ENSG00000091831, ENSG00000141736","protein expression, protein expression","Positve, negative","AND","ESR1 PROTEIN EXPRESSION POSITVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","Breast Cancer (Stage I-III)","MONDO_0007254","COX, Estrogen Receptors, DNA/DNA-topoisomerase II complex, DNA, Bcl2","pass","Tyler","Breast Cancer (LT NCT04194684, 1-50)_tyler.xlsx","clinicaltrials.gov","NCT04038489","BiomarkerKG-2085566364"
"130","NAB-PACLITAXEL",NA,"36314","ERBB2, ESR1, PR","ENSG00000141736, ENSG00000091831, ENSG00000134551","protein expression, protein expression, protein expression","Positive/Negative, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PR PROTEIN EXPRESSION NEGATIVE","primary invasive breast cancer and clinical stage I - III, first option Ⅳ","MONDO_0007254","Bcl2/GP60","pass","Tyler","Breast Cancer (LT NCT04194684, 1-50)_tyler.xlsx","clinicaltrials.gov","NCT03959397","BiomarkerKG-969815521"
"131","NIVOLUMAB, IPILIMUMAB","DB09035,DB06186","NA, NA","ERBB2, ER, PR","ENSG00000141736, ENSG00000091831, ENSG00000134551","protein expression, protein expression, protein expression","Negative, negative/positive, negative/positive","AND/OR, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND/OR ER PROTEIN EXPRESSION NEGATIVE/POSITIVE AND/OR PR PROTEIN EXPRESSION NEGATIVE/POSITIVE","metastatic breast cancer","EFO_1000984","PD1, CTLA4","pass","Tyler","Breast Cancer (LT NCT04194684, 1-50)_tyler.xlsx","clinicaltrials.gov","NCT03789110","BiomarkerKG613560300"
"132","SIMVASTATIN","DB00641","54454","ERBB2","ENSG00000141736","protein expression & amplification","Positive",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","Breast Cancer Stage (Stage IV)","MONDO_0007254","UNK","pass","Tyler","Breast Cancer (LT NCT04194684, 1-50)_tyler.xlsx","clinicaltrials.gov","NCT03324425","BiomarkerKG1251372237"
"133","PEMBROLIZUMAB, TAMOXIFEN","DB09037,DB00675","NA, 2733526","ESR1, ERBB2, PR","ENSG00000091831, ENSG00000141736, ENSG00000134551","mutation, protein expression, protein expression","Positve, negative, positive","AND, AND/OR","ESR1 MUTATION POSITVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE AND/OR PR PROTEIN EXPRESSION POSITIVE","Breast Cancer Female","MONDO_0007254","PD1, Estrogen Receptors","pass","Tyler","Breast Cancer (LT NCT04194684, 1-50)_tyler.xlsx","clinicaltrials.gov","NCT03879174","BiomarkerKG2106518615"
"134","APATINIB, PACLITAXEL, CISPLATIN","DB14765,DB01229,DB00515","45139106, 36314, 135804801","ERBB2","ENSG00000141736","protein expression","Negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","Breast Cancer","MONDO_0007254","VEGFR2, Bcl2, Replication and transcription of DNA","pass","Tyler","Breast Cancer (LT NCT04194684, 1-50)_tyler.xlsx","clinicaltrials.gov","NCT03982485","BiomarkerKG351003137"
"135","PALBOCICLIB","DB09073","11431660","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","protein expression, protein expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","Breast Cancer Stage (Stage II-III)","MONDO_0007254","CDK4/CDK6","pass","Tyler","Breast Cancer (LT NCT04194684, 1-50)_tyler.xlsx","clinicaltrials.gov","NCT03609047","BiomarkerKG-1579678160"
"137","DOCETAXEL, CARBOPLATIN, TRASTUZUMAB, PERTUZUMAB, EPIRUBICIN, CYCLOPHOSPHAMIDE, ATEZOLIZUMAB, TRASTUZUMAB EMTANSINE","DB01248,DB00958,DB00072,DB06366,DB00445,DB00531,DB11595,DB05773","148124, 56840877, 3001322, NA, 65348, 2907, NA, NA","ERBB2, ESR1, PR, PDl1","ENSG00000141736, ENSG00000091831, ENSG00000134551, ENSG00000120217","protein expression & amplification, protein expression, protein expression, protein expression","Positive, positive, positive, positve","AND, AND, AND","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PR PROTEIN EXPRESSION POSITIVE AND PDL1 PROTEIN EXPRESSION POSITVE","Early-stage Breast Cancer","MONDO_0007254","VEGF/microtubule, DNA/Protein, EBBR2, EBBR2,  DNA/DNA-topoisomerase II complex, DNA, CD274, microtubules","pass","Tyler","Breast Cancer (LT NCT04194684, 1-50)_tyler.xlsx","clinicaltrials.gov","NCT03894007","BiomarkerKG1821783061"
"138","OLAPARIB, VORINOSTAT","DB09074,DB02546","23725625, 5311","ERBB2","ENSG00000141736","protein expression","Negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","Breast Cancer Metastatic, Breast Cancer","MONDO_0007254","PARP, HDAC","pass","Tyler","Breast Cancer (LT NCT04194684, 1-50)_tyler.xlsx","clinicaltrials.gov","NCT03742245","BiomarkerKG1189074014"
"140","NIRAPARIB, TRASTUZUMAB","DB11793,DB00072","24958200, 3001322","ERBB2, ESR1, PR","ENSG00000141736, ENSG00000091831, ENSG00000134551","protein expression & amplification, protein expression, protein expression","Positive, negativie/positive, negative/positive","AND/OR, AND/OR","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND/OR ESR1 PROTEIN EXPRESSION NEGATIVIE/POSITIVE AND/OR PR PROTEIN EXPRESSION NEGATIVE/POSITIVE","Metastatic Breast Cancer, EBBR2 Positive Breast Carcinoma","MONDO_0007254","PARP1/PARP2, EBBR2","pass","Tyler","Breast Cancer (LT NCT04194684, 1-50)_tyler.xlsx","clinicaltrials.gov","NCT03368729","BiomarkerKG-388096993"
"141","DOCETAXEL, CARBOPLATIN, TRASTUZUMAB, PERTUZUMAB","DB01248,DB00958,DB00072,DB06366","148124, 56840877, 3001322, NA","ERBB2","ENSG00000141736","protein expression & amplification","Positve",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITVE","Invasive breast carcinoma","EFO_1000307","VEGF/microtuble, DNA/Protein, EBBR2, EBBR2","pass","Tyler","Breast Cancer (LT NCT04194684, 1-50)_tyler.xlsx","clinicaltrials.gov","NCT04094896","BiomarkerKG1874182044"
"144","NIVOLUMAB, PACLITAXEL, ANTHRACYCLINE, CYCLOPHOSPHAMIDE, ENDOCRINE THERAPY","DB09035,DB01229,NA,DB00531,NA","NA, 36314, NA, 2907, NA","ERBB2, ESR1, PR","ENSG00000141736, ENSG00000091831, ENSG00000134551","protein expression, protein expression, protein expression","Negative, positive, negative/positive","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PR PROTEIN EXPRESSION NEGATIVE/POSITIVE","Breast Cancer","MONDO_0007254","PD1, Bcl2, DNA/DNA-topoisomerase II complex, DNA,  hormone receptors","pass","Tyler","Breast Cancer (LT NCT04194684, 1-50)_tyler.xlsx","clinicaltrials.gov","NCT04109066","BiomarkerKG-403694518"
"146","RUCAPARIB","DB12332","9931954","ERBB2, ESR1, PR","ENSG00000141736, ENSG00000091831, ENSG00000134551","protein expression, protein expression, protein expression","negative, negative, negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PR PROTEIN EXPRESSION NEGATIVE","TNBC Breast Cancer  (Stage I-III)","MONDO_0007254","PDL1","pass","Tyler","Breast Cancer (LT NCT04194684, 1-50)_tyler.xlsx","clinicaltrials.gov","NCT03911453","BiomarkerKG1055961785"
"150","ERIBULIN","DB08871","11354606","ERBB2, ESR1, PR","ENSG00000141736, ENSG00000091831, ENSG00000134551","protein expression, protein expression, protein expression","Negative, negative/positive, negative/positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND/OR PR PROTEIN EXPRESSION NEGATIVE/POSITIVE","Metastatic Breast Cancer","EFO_1000984","Tubulin","pass","Tyler","Breast Cancer (LT NCT04194684, 1-50)_tyler.xlsx","clinicaltrials.gov","NCT03637868","BiomarkerKG1604727650"
"151","RIBOCICLIB, LETROZOLE OR ANASTROZOLE, GOSERELIN","DB11730,NA,DB00014","44631912, NA, 5311128","ERBB2, PR,ESR1","ENSG00000141736, ENSG00000134551, ENSG00000091831","protein expression, protein expression, protein expression","Negative, positive, positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND PR PROTEIN EXPRESSION POSITIVE AND/OR ESR1 PROTEIN EXPRESSION POSITIVE","Advanced Breast Cancer","MONDO_0007254","CDK4/CDK6, aromatase OR aromatase, GnRH receptors","pass","Tyler","Breast Cancer (LT NCT04194684, 1-50)_tyler.xlsx","clinicaltrials.gov","NCT03822468","BiomarkerKG1707410640"
"152","IPILIMUMAB, NIVOLUMAB","DB06186,DB09035","NA, NA","ERBB2, ESR1, PR","ENSG00000141736, ENSG00000091831, ENSG00000134551","protein expression, protein expression, protein expression","Negative, negative, negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PR PROTEIN EXPRESSION NEGATIVE","TNBC Breast Cancer","MONDO_0007254","CTLA4, PD1","pass","Tyler","Breast Cancer (LT NCT04194684, 1-50)_tyler.xlsx","clinicaltrials.gov","NCT03546686","BiomarkerKG751083782"
"154","PALBOCICLIB, EXEMESTANE, GOSERELIN","DB09073,DB00990,DB00014","11431660, 60198, 5311128","ERBB2, ESR1, PR","ENSG00000141736, ENSG00000091831, ENSG00000134551","protein expression, protein expression, protein expression","Negative, positive, positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PR PROTEIN EXPRESSION POSITIVE","Metastatic Breast Cancer","EFO_1000984","CDK4/CDK6, aromatase, GnRH receptors","pass","Tyler","Breast Cancer (LT NCT04194684, 1-50)_tyler.xlsx","clinicaltrials.gov","NCT02917005","BiomarkerKG145449339"
"155","ERIBULIN","DB08871","11354606","ERBB2, ESR1, PR","ENSG00000141736, ENSG00000091831, ENSG00000134551","protein expression, protein expression, protein expression","Negative, positive, positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PR PROTEIN EXPRESSION POSITIVE","locally-recurrent or metastatic breast cancer","MONDO_0007254","Tubulin","pass","Tyler","Breast Cancer (LT NCT04194684, 1-50)_tyler.xlsx","clinicaltrials.gov","NCT03795012","BiomarkerKG1604727650"
"156","RIBOCICLIB, LETROZOLE","DB11730,DB01006","44631912, 3902","ERBB2, ESR1, PR","ENSG00000141736, ENSG00000091831, ENSG00000134551","protein expression, protein expression, protein expression","Negative, Positive, negative/positive","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND PR PROTEIN EXPRESSION NEGATIVE/POSITIVE","non-metastatic primary luminal breast cancer (Stage II-III)","MONDO_0007254","UNK","pass","Tyler","Breast Cancer (LT NCT04194684, 1-50)_tyler.xlsx","clinicaltrials.gov","NCT03283384","BiomarkerKG233970655"
"158","PEMBROLIZUMAB, TRASTUZUMAB BIOSIMILAR ABP 980, PERTUZUMAB","DB09037,NA,DB06366","NA, NA, NA","ERBB2, ESR1, PR","ENSG00000141736, ENSG00000091831, ENSG00000134551","protein expression & amplification, protein expression, protein expression","Positive, negative/positive, negative/positive","AND/OR, AND/OR","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE AND/OR ESR1 PROTEIN EXPRESSION NEGATIVE/POSITIVE AND/OR PR PROTEIN EXPRESSION NEGATIVE/POSITIVE","Breast Cancer","MONDO_0007254","UNK","pass","Tyler","Breast Cancer (LT NCT04194684, 1-50)_tyler.xlsx","clinicaltrials.gov","NCT03988036","BiomarkerKG-246127579"
"159","CFI-400945, DURVALUMAB","NA,DB11714","58486178, NA","ERBB2, ESR1, PR","ENSG00000141736, ENSG00000091831, ENSG00000134551","protein expression, protein expression, protein expression","Negative, negative, negative","AND, AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE AND PR PROTEIN EXPRESSION NEGATIVE","TNBC Breast Cancer","MONDO_0007254","PLK4, PDl1","pass","Tyler","Breast Cancer (LT NCT04194684, 1-50)_tyler.xlsx","clinicaltrials.gov","NCT04176848","BiomarkerKG-1294313271"
"160","RIBOCICLIB, LETROZOLE OR ANASTROZOLE, GOSERELIN","DB11730,NA,DB00014","44631912, NA, 5311128","ERBB2, ESR1, PR","ENSG00000141736, ENSG00000091831, ENSG00000134551","protein expression, protein expression, protein expression","Negative, positive, positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PR PROTEIN EXPRESSION POSITIVE","Premenopausal or perimenopausal locally advanced or metastatic breast cancer","MONDO_0007254","UNK","pass","Tyler","Breast Cancer (LT NCT04194684, 1-50)_tyler.xlsx","clinicaltrials.gov","NCT03839823","BiomarkerKG1823593815"
"161","NAB-PACLITAXEL",NA,"36314","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","protein expression, protein expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","Recurrent or metastatic breast cancer","MONDO_0007254","UNK","pass","Tyler","Breast Cancer (LT NCT04194684, 1-50)_tyler.xlsx","clinicaltrials.gov","NCT04194684","BiomarkerKG1596444665"
"163","NIVOLUMAB, IPILIMUMAB","DB09035,DB06186","NA, NA","ESR1, PR, ERBB2","ENSG00000091831, ENSG00000134551, ENSG00000141736","Protein Expression, Protein expression, Protein Expression","Negative, Negative, Negative","AND, AND","ESR1 PROTEIN EXPRESSION NEGATIVE AND PR PROTEIN EXPRESSION NEGATIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","Triple negative Breast Cancer","EFO_0005537","PD1, CTLA4","pass","Austin","Breast Cancer (LT NCT04001621, 1-50)_austin.xlsx","clinicaltrials.gov","NCT03818685","BiomarkerKG340012207"
"164","IMIPRAMINE","DB00458","8228","ESR1, PR, ERBB2","ENSG00000091831, ENSG00000134551, ENSG00000141736","Protein Expression, Protein expression, Protein Expression & amplification","Negative, Negative, Negative","AND, AND","ESR1 PROTEIN EXPRESSION NEGATIVE AND PR PROTEIN EXPRESSION NEGATIVE AND ERBB2 PROTEIN EXPRESSION & AMPLIFICATION NEGATIVE","Triple negative Breast Cancer","EFO_0005537","FoxM1","pass","Austin","Breast Cancer (LT NCT04001621, 1-50)_austin.xlsx","clinicaltrials.gov","NCT03122444","BiomarkerKG-2064171984"
"166","PALBOCICLIB, LETROZOLE","DB09073,DB01006","11431660, 3902","ERBB2, PR, ESR1","ENSG00000141736, ENSG00000134551, ENSG00000091831","Protein Expression, Protein expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND PR PROTEIN EXPRESSION POSITIVE AND/OR ESR1 PROTEIN EXPRESSION POSITIVE","Breast Cancer","MONDO_0007254","CDK4/CDK6, aromatase","pass","Austin","Breast Cancer (LT NCT04001621, 1-50)_austin.xlsx","clinicaltrials.gov","NCT04047758","BiomarkerKG-409972175"
"168","PYROTINIB, ETOPOSIDE","DB14993,DB00773","51039030, 36462","ERBB2","ENSG00000141736","Protein Expression & Amplification","Positive",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","Locally Advanced or Metastatic Breast Cancer","MONDO_0007254","ERBB2, Topoisomerase II/DNA","pass","Austin","Breast Cancer (LT NCT04001621, 1-50)_austin.xlsx","clinicaltrials.gov","NCT03923179","BiomarkerKG809776760"
"169","DOCETAXEL, RITONAVIR","DB01248,DB00503","148124, 392622","ERBB2","ENSG00000141736","Protein Expression","Negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","Recurrent Breast Cancer","MONDO_0007254","Microtubles, UNK","pass","Austin","Breast Cancer (LT NCT04001621, 1-50)_austin.xlsx","clinicaltrials.gov","NCT03890744","BiomarkerKG-1915782920"
"170","DURVALUMAB, TRASTUZUMAB, PERTUZUMAB","DB11714,DB00072,DB06366","NA, 3001322, NA","ERBB2, PR, ESR1","ENSG00000141736, ENSG00000134551, ENSG00000091831","Protein Expression & Amplification/Protein Expression, Protein Expression, Protein Expression","Positive, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND PR PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE","Breast Cancer (I-II)","MONDO_0007254","PDL1, ERBB2, ERBB2","pass","Austin","Breast Cancer (LT NCT04001621, 1-50)_austin.xlsx","clinicaltrials.gov","NCT03820141","BiomarkerKG-945630217"
"171","PACLITAXEL, TRASTUZUMAB, CARBOPLATIN, PERTUZUMAB","DB01229,DB00072,DB00958,DB06366","36314, 3001322, 56840877, NA","ERBB2, PR, ESR1","ENSG00000141736, ENSG00000134551, ENSG00000091831","Protein Expression & Amplification/Protein Expression, Protein Expression, Protein Expression","Positive, Negative, Negative","AND, AND","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND PR PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION NEGATIVE","Breast Cancer (Stage II-III)","MONDO_0007254","Bcl2, ERBB2, DNA/Protein, ERBB2","pass","Austin","Breast Cancer (LT NCT04001621, 1-50)_austin.xlsx","clinicaltrials.gov","NCT03820063","BiomarkerKG-735683940"
"172","ONAPRISTONE","DB12637","5311505","ESR1, PR, ERBB2, Ki67","ENSG00000091831, ENSG00000134551, ENSG00000141736, ENSG00000148773","Protein Expression, Protein expression, Protein Expression, Protein expression","Positive, Positive, Negative, Positive","AND, AND, AND","ESR1 PROTEIN EXPRESSION POSITIVE AND PR PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE AND KI67 PROTEIN EXPRESSION POSITIVE","Breast Cancer (I-II)","MONDO_0007254","progesterone receptor","pass","Austin","Breast Cancer (LT NCT04001621, 1-50)_austin.xlsx","clinicaltrials.gov","NCT04142892","BiomarkerKG-531346711"
"173","PEMBROLIZUMAB, PEGYLATED LIPOSOMAL DOXORUBICIN","DB09037,NA","NA, NA","ESR1, ERBB2","ENSG00000091831, ENSG00000141736","Protein Expression, Protein Expression","Positive, Negative","AND","ESR1 PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE","Metastatic Breast Cancer (III-IV)","MONDO_0007254","PD1, Topoisomerase II/DNA","pass","Austin","Breast Cancer (LT NCT04001621, 1-50)_austin.xlsx","clinicaltrials.gov","NCT03591276","BiomarkerKG-859329038"
"174","PYROTINIB, CAPECITABINE","DB14993,DB01101","51039030, 60953","ERBB2","ENSG00000141736","Protein Expression & Amplification","Positive",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION POSITIVE","Breast Cancer","MONDO_0007254","ERBB2, DNA/RNA/Protein Synthesis","pass","Austin","Breast Cancer (LT NCT04001621, 1-50)_austin.xlsx","clinicaltrials.gov","NCT03923166","BiomarkerKG687053448"
"175","PEMBROLIZUMAB, PACLITAXEL","DB09037,DB01229","NA, 36314","ESR1, ERBB2, Ki67","ENSG00000091831, ENSG00000141736, ENSG00000148773","Protein Expression, Protein expression, Protein Expression","Positive, Negative, Positive","AND, AND","ESR1 PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE AND KI67 PROTEIN EXPRESSION POSITIVE","Locally Advanced or Metastatic Luminal B Breast Cancer","MONDO_0007254","PDL, Bcl2","pass","Austin","Breast Cancer (LT NCT04001621, 1-50)_austin.xlsx","clinicaltrials.gov","NCT03841747","BiomarkerKG-889764113"
"176","PYROTINIB, ALBUMIN-BOUND PACLITAXEL, TRASTUZUMAB, EPRIRUBICIN, CYCLOPHOSPHAMIDE","DB14993,NA,DB00072,NA,DB00531","51039030, NA, 3001322, NA, 2907","ERBB2","ENSG00000141736","Protein Expression &Amplification/Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION &AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","Breast Cancer (I-III)","MONDO_0007254","ERBB2, GP60/Bcl2, ERBB2, Topoisomerase II/DNA, DNA","pass","Austin","Breast Cancer (LT NCT04001621, 1-50)_austin.xlsx","clinicaltrials.gov","NCT04066790","BiomarkerKG-103720969"
"181","LETROZOLE, PYROTINIB, SHR6390","DB01006,DB14993,NA","3902, 51039030, NA","ERBB2, ESR1, PR","ENSG00000141736, ENSG00000091831, ENSG00000134551","Protein Expression & Amplification/Protein Expression, Protein Expression, Protein Expression","Positive, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION & AMPLIFICATION/PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PR PROTEIN EXPRESSION POSITIVE","Metastatic Breast Cancer","EFO_1000984","Aromatase, ERBB2, CDK4/CDK6","pass","Austin","Breast Cancer (LT NCT04001621, 1-50)_austin.xlsx","clinicaltrials.gov","NCT03772353","BiomarkerKG471505800"
"182","CAPECITABINE","DB01101","60953","ERBB2, ESR1, PR","ENSG00000141736, ENSG00000091831, ENSG00000134551","Protein Expression, Protein expression, Protein Expression","Negative, Positive/Negative, Positive/Negative","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PR PROTEIN EXPRESSION POSITIVE/NEGATIVE","Non-metastatic Invasive Breast Cancer","MONDO_0007254","DNA/RNA/Protein Synthesis","pass","Austin","Breast Cancer (LT NCT04001621, 1-50)_austin.xlsx","clinicaltrials.gov","NCT03958721","BiomarkerKG-2133494385"
"183","DOCETAXEL, CYCLOPHOSPHAMIDE, TRASTUZUMAB","DB01248,DB00531,DB00072","148124, 2907, 3001322","ERBB2","ENSG00000141736","Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION POSITIVE","Breast Neoplasms","MONDO_0007254","microtubles/VEGF, DNA, ERBB2","pass","Austin","Breast Cancer (LT NCT04001621, 1-50)_austin.xlsx","clinicaltrials.gov","NCT03705429","BiomarkerKG-435072881"
"184","PYROTINIB","DB14993","51039030","ERBB2","ENSG00000141736","Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION POSITIVE","Breast Cancer (IIA-III)","MONDO_0007254","ERBB2","pass","Austin","Breast Cancer (LT NCT04001621, 1-50)_austin.xlsx","clinicaltrials.gov","NCT04126525","BiomarkerKG-1504794440"
"185","SAR439859",NA,"130232326","ERBB2, ESR1","ENSG00000141736, ENSG00000091831","Protein Expression, Protein Expression","Negative, Positive","AND","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE","Locally Advanced or Metastatic Breast Cancer","MONDO_0007254","ESR1","pass","Austin","Breast Cancer (LT NCT04001621, 1-50)_austin.xlsx","clinicaltrials.gov","NCT03816839","BiomarkerKG1596444665"
"186","CAPECITABINE","DB01101","60953","ERBB2, ESR1, PR","ENSG00000141736, ENSG00000091831, ENSG00000134551","Protein Expression, Protein expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PR PROTEIN EXPRESSION POSITIVE","Breast Cancer","MONDO_0007254","DNA/RNA/Protein Synthesis","pass","Austin","Breast Cancer (LT NCT04001621, 1-50)_austin.xlsx","clinicaltrials.gov","NCT03638648","BiomarkerKG-2133494385"
"187","IPATASERTIB, PALBOCICLIB, FULVESTRANT","DB11743,DB09073,DB00947","24788740, 11431660, 104741","ERBB2, ESR1, PR","ENSG00000141736, ENSG00000091831, ENSG00000134551","Protein Expression, Protein expression, Protein Expression","Negative, Positive, Positive","AND, AND/OR","ERBB2 PROTEIN EXPRESSION NEGATIVE AND ESR1 PROTEIN EXPRESSION POSITIVE AND/OR PR PROTEIN EXPRESSION POSITIVE","Locally Advanced Unresectable or Metastatic Breast Cancer","MONDO_0007254","Akt, CDK4/CDK6, ER","pass","Austin","Breast Cancer (LT NCT04001621, 1-50)_austin.xlsx","clinicaltrials.gov","NCT04060862","BiomarkerKG668649648"
"188","ERIBULIN, BALIXAFORTIDE","DB08871,DB15370","11354606, 138752609","ERBB2","ENSG00000141736","Protein Expression","Negative",NA,"ERBB2 PROTEIN EXPRESSION NEGATIVE","Locally Recurrent or Metastatic Breast Cancer","MONDO_0007254","UNK, UNK","pass","Austin","Breast Cancer (LT NCT04001621, 1-50)_austin.xlsx","clinicaltrials.gov","NCT03786094","BiomarkerKG1503939067"
"190","VENETOCLAX, PALBOCICLIB, LETROZOLE","DB11581,DB09073,DB01006","49846579, 11431660, 3902","ESR1, Bcl2, ERBB2","ENSG00000091831, ENSG00000171791, ENSG00000141736","Protein Expression, Protein expression, Protein Expression","Positive, Positive, Positive","AND, AND/OR","ESR1 PROTEIN EXPRESSION POSITIVE AND BCL2 PROTEIN EXPRESSION POSITIVE AND/OR ERBB2 PROTEIN EXPRESSION POSITIVE","Locally advanced or metastatic breast cancer","MONDO_0007254","UNK, CDK4/CDK6, aromatase","pass","Austin","Breast Cancer (LT NCT04001621, 1-50)_austin.xlsx","clinicaltrials.gov","NCT03900884","BiomarkerKG-2032842044"
"192","ATEZOLIZUMAB, DOXORUBICIN, CYCLOPHOSPHAMIDE, PACLITAXEL, PERTUZUMAB, TRASTUZUMAB EMTANSINE","DB11595,DB00997,DB00531,DB01229,DB06366,DB05773","NA, 443939, 2907, 36314, NA, NA","ERBB2, ESR1, PR, PDL1","ENSG00000141736, ENSG00000091831, ENSG00000134551, ENSG00000120217","Protein Expression, Protein expression, Protein Expression, Protein expression","Positive, Positive/Negative, Positive/Negative, Positive/Negative","AND, AND/OR, AND/OR","ERBB2 PROTEIN EXPRESSION POSITIVE AND ESR1 PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PR PROTEIN EXPRESSION POSITIVE/NEGATIVE AND/OR PDL1 PROTEIN EXPRESSION POSITIVE/NEGATIVE","Breast Cancer (I-III)","MONDO_0007254","UNK, UNK, UNK, UNK, UNK, UNK","pass","Austin","Breast Cancer (LT NCT04001621, 1-50)_austin.xlsx","clinicaltrials.gov","NCT03726879","BiomarkerKG1511175762"
"193","FS-1502",NA,"2760428","ERBB2","ENSG00000141736","Protein Expression & Amplification/Protein Expression","Positive",NA,"ERBB2 PROTEIN EXPRESSION & AMPLIFICATION/PROTEIN EXPRESSION POSITIVE","Locally advanced or metastatic breast cancer","MONDO_0007254","ERBB2","pass","Austin","Breast Cancer (LT NCT04001621, 1-50)_austin.xlsx","clinicaltrials.gov","NCT03944499","BiomarkerKG1623818552"
"195","ALL-TRANS RETINOIC ACID, ANASTROZOLE","NA,DB01217","444795, 2187","ESR1, ERBB2, Ki67","ENSG00000091831, ENSG00000141736, ENSG00000148773","Protein Expression, Protein expression, Protein Expression","Positive, Negative, Positive","AND, AND","ESR1 PROTEIN EXPRESSION POSITIVE AND ERBB2 PROTEIN EXPRESSION NEGATIVE AND KI67 PROTEIN EXPRESSION POSITIVE","Breast Neoplasm","EFO_0003869","RARα, UNK","pass","Austin","Breast Cancer (LT NCT04001621, 1-50)_austin.xlsx","clinicaltrials.gov","NCT04113863","BiomarkerKG-1795461556"
"197","BAVITUXIMAB, SORAFENIB","DB05136,DB00398","NA, 406563","AFP","ENSG00000081051","Protein Expression","Positive",NA,"AFP PROTEIN EXPRESSION POSITIVE","Locally Advanced or Metastatic Hepatocellular Carinoma","EFO_0009709","UNK/UNK","pass","Austin","Livercancer2010_2011.xlsx","clinicaltrials.gov","NCT01264705","BiomarkerKG626426273"
"198","PD-0332991",NA,"5330286","RB","ENSG00000139687","Protein Expression","Positive",NA,"RB PROTEIN EXPRESSION POSITIVE","Advanced Hepatocellular Carcinoma","EFO_0009260","CDK4/CDK6","pass","Austin","Livercancer2010_2011.xlsx","clinicaltrials.gov","NCT01356628","BiomarkerKG-1504368928"
"204","EVEROLIMUS, PASIREOTIDE","DB01590,DB06663","6442177, 9941444","AFP","ENSG00000081051","Protein Expression","Positive",NA,"AFP PROTEIN EXPRESSION POSITIVE","Advanced or Metastatic Hepatocellular Carcinoma","EFO_0009260","UNK, UNK","pass","Austin","Livercancer2010_2011.xlsx","clinicaltrials.gov","NCT01488487","BiomarkerKG936726893"
"221","SORAFENIB TOSYLATE, VORINOSTAT","NA,DB02546","406563, 5311","AFP","ENSG00000081051","Protein Expression","Positive",NA,"AFP PROTEIN EXPRESSION POSITIVE","Advanced hepatocellular carcinoma","EFO_0009260",NA,"pass","Austin","Livercancer2010_2011.xlsx","clinicaltrials.gov","NCT01075113","BiomarkerKG1436097858"
